Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.46 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660737 | 1.00 | KDM4E (0.46) | KDM4ECISD1SLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL662534 | 0.89 | ALDH1A1 (0.47) | KDM4EALDH1A1HPGDMAPTGAA | |
| SCHEMBL4533767 | 0.86 | MAPT (0.41) | KDM4ECISD1SLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL4533775 | 0.86 | MAPT (0.41) | KDM4ECISD1SLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL9360740 | 0.79 | CISD1 (0.56) | KDM4ECISD1SLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL9365514 | 0.79 | CISD1 (0.56) | KDM4ECISD1SLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL9360741 | 0.79 | CISD1 (0.56) | KDM4ECISD1SLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL9365521 | 0.79 | CISD1 (0.56) | KDM4ECISD1SLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL662535 | 0.77 | ALDH1A1 (0.43) | KDM4EALDH1A1MAPTNPC1 | |
| SCHEMBL662536 | 0.77 | ALDH1A1 (0.43) | KDM4EALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2012-02-23 | — | — | US | disclosed |
| US-8063105-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| US-20090281103-A1 | Renin Inhibitors | MERCK CANADA INC. (CA) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | KDM4E 3884/4885CISD1 4249/4885SLC16A3 2648/4885 |
| US-20090281103-A1 | Renin Inhibitors | REN, ACE, AGT | KDM4E 3615/4885CISD1 4474/4885SLC16A3 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.